References
- Van CutsemEKöhneCHHitreECetuximab and chemotherapy as initial treatment for metastatic colorectal cancerN Engl J Med20093601408141719339720
- BanckMSGrotheyABiomarkers of resistance to epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancerClin Cancer Res2009157492750120008849
- Van CutsemELangID’HaensGKRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experienceJ Clin Oncol200826Suppl 2 Abstr 2
- BokemeyerCBondarenkoIHartmannJTEfficacy according to bio-marker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS studyAnn Oncol2011221535154621228335
- DahabrehIJTerasawaTCastaldiPJTrikalinosTSystematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancerAnn Intern Med2011154374921200037
- Van CutsemEKöhneCHLángICetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation statusJ Clin Oncol2011292011201921502544
- AmadoRGWolfMPeetersMWild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancerJ Clin Oncol2008261626163418316791
- JimenoAMessersmithWAHirschFRFranklinWAEckhardtSGKRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selectionJ Clin Oncol2009271130113619124802
- GaoJLiYYSunPNShenLComparative analysis of dideoxy sequencing, the KRAS strip assay and pyrosequencing for detection of KRAS mutationWorld J Gastroenterol2010164858486420939116
- SundströmMEdlundKLindellMKRAS analysis in colorectal carcinoma: analytical aspects of pyrosequencing and allele-specific PCR in clinical practiceBMC Cancer20101066066921122130
- FranklinWAHaneyJSugitaMBemisLJimenoAMessersmithWAKRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancerJ Mol Diagn201012435020007845
- BihlMPHoellerSAndreozziMCKRAS mutations testing in colorectal cancer: comparison of the results obtained using 3 different methods for the analysis of codons G12 and G13Diagn Mol Pathol201221142322306671
- FrenchDSmithAPowersMPWuAHKRAS mutation detection in colorectal cancer by a commercially available gene chip array compares well with Sanger sequencingClin Chim Acta20114121578158121575616
- LeeSBrophyVHCaoJAnalytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinomaVirchows Arch201246014114922173329
- Gonzalez de CastroDAnguloBGomezBA comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimensBr J Cancer201210734535122713664
- RonaghiMUhlénMNyrénPA sequencing method based on real-time pyrophosphateScience19982813633659705713
- CrossJDxS LtdPharmacogenomics2008946346718384259
- Autogenomics.com [homepage on the Internet]Autogenomics Inc.http://www.autogenomics.com/cancer_KRAS-BRAF.php Available from: http://www.autogenomics.com/Accessed June 18, 2013
- 454.com. 454.com [homepage on the Internet]454 Life Sciences, a Roche Companyhttp://454.com/downloads/GSJuniorSystem_Brochure.pdf Available from: http://www.454.com/Accessed June 18, 2013
- Aiom.it [homepage on the Internet]Associazione Italiana di Oncologia Medicahttp://www.aiom.it/area+pubblica/area+medica/prodotti+scientifici/position+paper/Raccomandazioni%20per%20l'analisi%20mutazionale%20del%20gene%20KRAS%20nel%20carcinoma%20del%20colon-retto/1,1006,1 Available from: http://www.Aiom.it/Accessed June 18, 2013
- van KriekenJHJungAKirchnerTKRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance programVirchows Arch200845341743118802721
- HosteinILamyAFaurNThe detection of double mutations in KRAS depends on the mutation-detection assay usedClin Chem2011571077107921441420
- ZhouQZhangXCChenZHRelative abundance of EGFR mutations predicts benefit from Gefitinib treatment for advanced non small cell lung cancerJ Clin Oncol2011293316332121788562